AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$254.64-0.05%
Close 2026-07-07 · 1-day change
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→AbbVie grows revenue about 10% a year. It raised 2026 EPS guidance to about $14.28. The company invests $1.4 billion in manufacturing and expands its drug pipeline. It also increased its dividend by 5.5%.
Legal probes into China trials could hurt AbbVie's regulatory approvals. Acquired R&D expenses remain high, pressuring earnings. A small earnings miss in Q1 2026 shows risks to growth.
The price is about 9% above our fair value near $232. Analysts expect about 10% revenue growth. Our fair value is 12% below the Street median, reflecting some caution versus the Street's optimism.
Breaks if: Capital investments fall significantly below $1.78 billion in 2026
Invest in new manufacturing facilities and R&D capabilities to support growth and innovation.
Stated as a priority in 3 of last 6 quarters. AbbVie announced significant capital investments including $1.4 billion for a new manufacturing campus in Durham, NC, and $380 million for API facilities in North Chicago in 2026-Q1, plus ongoing R&D investments. These announcements show active delivery on expanding manufacturing and R&D capabilities.
Breaks if: Dividend per share falls below $1.64 or is cut
Continue increasing quarterly cash dividend to return cash to shareholders.
Stated as a priority in 4 of last 6 quarters. AbbVie increased its quarterly dividend from $1.64 in 2025-Q4 to $1.73 in 2026-Q1, reflecting a 5.5% increase. The company has consistently raised dividends since 2013 by over 330%, demonstrating delivery on dividend growth commitments.
Breaks if: adjusted diluted EPS falls below $13.96 in 2026
Raise and maintain full-year adjusted diluted EPS guidance reflecting growth and pipeline progress.
Stated as a priority in 6 of last 6 quarters. AbbVie raised its full-year adjusted diluted EPS guidance from $13.96 - $14.16 to $14.08 - $14.28 in 2026-Q1 and maintained a Q2 2026 EPS guidance range of $3.57 - $3.61. This reflects consistent upward revisions and delivery on growth expectations, matching management's stated priority.
Breaks if: Significant regulatory setbacks or failure to advance key drugs like Skyrizi, Rinvoq, or Epkinly
Progress clinical pipeline and secure regulatory approvals for key products including Skyrizi, Rinvoq, Epkinly, and others.
Stated as a priority in 6 of last 6 quarters. Management consistently reported regulatory submissions and approvals for key pipeline products including Skyrizi, Rinvoq, Epkinly, and Elahere, as well as strategic acquisitions to bolster the pipeline. This demonstrates ongoing delivery on advancing the pipeline and regulatory progress.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Announced $1.4 billion investment to build a pharmaceutical manufacturing campus in Durham, NC.”
“Started construction on $195 million API facility in North Chicago and $70 million biologics expansion in Worcester.”
“Announced $100 billion U.S. R&D and capital investments over next decade under voluntary agreement.”
“Dividend per share increased to $1.73 from $1.64 starting February 2026.”
“Dividend per share was $1.73, up from $1.64 in prior quarters.”
“Announced 5.5% dividend increase beginning February 2026.”
“Dividend per share was $1.64, increased from $1.55 in 2024.”
“AbbVie’s second-quarter 2026 adjusted diluted earnings per share guidance range is $3.57 - $3.61.”
“Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28.”
“Provides 2026 Adjusted Diluted EPS Guidance Range of $14.37 to $14.57.”
“Raises 2025 Adjusted Diluted EPS Guidance Range from $10.38 - $10.58 to $10.61 - $10.65.”
“Raises 2025 Adjusted Diluted EPS Guidance Range from $11.67 - $11.87 to $11.88 - $12.08.”
“Raises 2025 Adjusted Diluted EPS Guidance Range from $11.99 - $12.19 to $12.09 - $12.29.”
“AbbVie submitted FDA applications for Skyrizi in Crohn’s disease and Rinvoq in alopecia areata.”
“FDA approved Epkinly for follicular lymphoma; positive Phase 3 data for Elahere.”
“FDA approval of Rinvoq for giant cell arteritis; positive Phase 3 data for alopecia areata.”
“FDA approved Rinvoq for giant cell arteritis; positive topline results for Rinvoq in alopecia areata.”
“European Commission granted marketing authorization to Rinvoq for giant cell arteritis.”
“FDA approved Epkinly; positive data for Elahere; acquisition of Aliada Therapeutics.”